– USA, CA – Faeth Therapeutics Inc. a clinical biotechnology company focused on rethinking the science of cancer using metabolism, announced the appointments of Dr. Stephen Hahn and Dr. Jayson Dallas (MD) to its Board of Directors.
About Dr. Stephen Hahn
Dr. Stephen Hahn, a renowned radiation oncologist and former Chief Medical Executive of MD Anderson Cancer Center, brings decades of experience in oncology, regulatory affairs, and leadership across both public and private sectors. His expertise in cancer treatment and his role as the 24th Commissioner of the Food and Drug Administration uniquely position him to guide Faeth’s clinical and regulatory progress.
“Metabolism has been one of the most problematic aspects of oncology for pharmaceutical and biotech companies to understand and harness,” said Dr. Stephen Hahn. “Faeth’s approach of leveraging metabolic research in combination with AI has opened up metabolism as a new pillar in the treatment of cancer.”
About Dr. Jayson Dallas
Dr. Jayson Dallas adds a wealth of commercial and operational expertise to Faeth. Currently CEO at Rivus Pharmaceuticals, he previously led the successful acquisition of Aimmune Therapeutics by Nestlé Health Science and held key leadership roles at Ultragenyx, Genentech, and Novartis. He is an endocrinologist experienced in driving biotech companies from early-stage development through successful commercialization.
Dr. Jayson Dallas said: “Faeth’s innovative approach to targeting cancer metabolism has the potential to transform treatment paradigms and unlock new drugs for development. I look forward to contributing to its continued success.”
About Faeth Therapeutics
Faeth Therapeutics is a clinical-stage biotechnology company at the forefront of oncology with a robust clinical and preclinical pipeline powered by its AI-driven MetabOS discovery platform. Faeth’s lead program, PIKTOR, has shown outstanding clinical results in a Phase 1b trial and is advancing into a Phase 2 trial in endometrial cancer in 2024.
For more information: https://www.faeththerapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.